手法を比較

	ランダム化比較試験のためのコクランのリスク・バイアス評価ツール2.0	GRADEエビデンスプロファイリング：エビデンスの確実性と推奨の強さの評価
分野	研究方法論	研究方法論
系統	Process / pipeline	Process / pipeline
提唱年	2019	2008
提唱者	Jonathan Sterne, Julian Higgins (Cochrane Collaboration)	Guyatt et al. (GRADE Working Group)
種類	Clinician-rated / Research team assessment	Research team / Guideline panel assessment
原典	Sterne, J. A., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., ... & Higgins, J. P. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898.	Guyatt, G., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336(7650), 924–926.
別名	RoB 2.0, RoB 2	GRADE, GRADE approach
関連	4	4
概要	RoB 2 is the Cochrane Collaboration's updated methodology for assessing the risk of bias in randomized controlled trials (RCTs). Published in 2019, it replaced the original Cochrane RoB tool with a more structured, transparent approach using signalling questions and domain-based judgments to evaluate five critical sources of bias.	GRADE (Grading of Recommendations Assessment, Development and Evaluation) is a systematic, transparent framework for assessing the certainty of evidence and determining the strength of clinical recommendations in healthcare. Published in 2008 by Guyatt et al., GRADE has become the international standard for guideline development, used by the World Health Organization, Cochrane, and most major clinical guideline organizations worldwide.